서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 27 of 27

Issue DateTitle / Author(s) / CitationFileAltmetrics
1998-01
Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II)
DOI
1999-10
Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma
DOI
2001-04
A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies
DOI
2003-12
Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors
DOI
2004-08
Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
DOI
2008-01
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
DOI
2008-03
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You

Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615

DOI
2008-06
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
DOI
2008-12
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
DOI
2011-02
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
DOI
2011-07
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
DOI
2011-12
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
DOI
2012-04
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Park, Eunju; Park, Jinah; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue

International Journal of Oncology, Vol.40 No.4, pp.1259-1266

DOI
2016-01
Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors
DOI
2016-03
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
DOI
2016-07
Src as a Therapeutic Target in Biliary Tract Cancer
DOI
2017-01
Inhibition of allergic response by intranasal selective NF-κB decoy oligodeoxynucleotides in a murine model of allergic rhinitis

Wee, Jee Hye; Zhang, Yu-Lan; Rhee, Chae-Seo; Kim, Dong-Young

Allergy, Asthma & Immunology Research, Vol.9 No.1, pp.61-69

DOI
2017-02
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
DOI
2017-08
Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer
DOI
2017-10
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-02
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
DOI
2019-06
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea
view fileDOI
2019-07
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
DOI
2020-01
HER2-targeted therapies - a role beyond breast cancer

Oh, Do-Youn; Bang, Yung-Jue

Nature Reviews Clinical Oncology, Vol.17 No.1, pp.33-48

DOI
2021-12
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
DOI
1